Allergy Therapeutics Share Chat (AGY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Allergy Therapeutics	LSE:AGY	London	Ordinary Share	GB00B02LCQ05	ORD 0.1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	26.25p	25.50p	27.00p	26.25p	26.25p	26.25p	48,081	05:30:39

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	64.1	-2.0	-0.4	-	169.08

Allergy Therapeutics Share Discussion Threads

Showing 3551 to 3575 of 3575 messages

Chat Pages: 143 142 141 140 139 138 137 136 135 134 133 132 Older

Date	Subject	Author	Discuss
22/7/2018 22:44	What is the latest broker forecast for the sp? Thanks.	farmergeorge	Read Full Thread Reply
19/7/2018 11:50	Yes, earlier than expected but good tactics to raise funds on the back of positive news. If new investors are brought on board it can lead to a price rise as they look to accumulate their desired position.	maddox	Read Full Thread Reply
19/7/2018 07:28	Funding was expected but this is sooner than I imagined which I think is a good thing given the ever-expanding business opportunities and the intention to accelerate product development. May not be much impact on the share price and the placing price is encouraging	audigger	Read Full Thread Reply
19/7/2018 07:16	TRANSFORMATIONAL!	jimmyloser	Read Full Thread Reply
12/7/2018 12:52	Solid. Suspect 2018 has been rather more pollen rich than 2017. Q4 2018 looks to be a defining period for AGY	audigger	Read Full Thread Reply
12/7/2018 07:30	Agreed Rich/ it is those trial results that will set this alight! Timed to come on or about results statement in September? impo/dyor	jimmyloser	Read Full Thread Reply
12/7/2018 07:18	A good solid set of results, hopefully trial results are good in Q3	richsawko	Read Full Thread Reply
04/7/2018 19:00	Last year on July 18th we had a Trading update. This one this year if they release one should be a cracker! impo/dyor	jimmyloser	Read Full Thread Reply
04/7/2018 16:15	Ah, filling a gap. thanks for response.	stefanj26	Read Full Thread Reply
04/7/2018 15:52	I cannot explain it but that is what the chart indicates. Maybe an overhang filling a sale holding the price back + although I have given up on predicting this market	richsawko	Read Full Thread Reply
04/7/2018 15:46	Forgive my ignorance, why would a big sell cause a rise in price rather than a fall?	stefanj26	Read Full Thread Reply
04/7/2018 15:22	The last time this happened in mid June we had a big jump in price - hoping for the same again!	richsawko	Read Full Thread Reply
04/7/2018 15:20	Massive sell trades today at 27p? Anyone know of a reason	richsawko	Read Full Thread Reply
29/6/2018 16:31	Tipped in today’s IC, but reveals nothing all of us here didn’t already know. Pleasing all the same.	dozey3	Read Full Thread Reply
25/6/2018 08:54	Some momentum building!	audigger	Read Full Thread Reply
25/6/2018 07:56	Allergy Therapeutics PLC 25 June 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the publication of positive data in the journal Immunotherapy, demonstrating long-lasting efficacy of Pollinex Quattro Grass in patients with grass pollen allergy. Zielen et al., Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. doi; 10.2217/imt-2018-0004 (ePub ahead of print). The observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. Each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy. The study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment. Professor Stefan Zielen, author of the paper commented; "We are delighted with the publication of our observational study that demonstrates the long-term effects of Pollinex Quattro Grass immunotherapy. Our paper highlights the benefits that this allergen-specific immunotherapy can offer allergy sufferers, in terms of patient convenience, as well as the potential for positive and long-lasting effects." Manuel Llobet, CEO at Allergy Therapeutics, said: "This paper validates earlier studies indicating Pollinex Quattro is disease modifying for the many patients affected by grass allergy. Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates. We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market." The data presented supports earlier studies investigating Pollinex Quattro, Zielen et al., 2007(1) and Rabe et al 2017(2) . Sustained efficacy according to European Medicine Agency criteria in 3114 patients was shown in the 2007 Zielen paper(1) , where after 3 years, improvement of symptoms was reported in more than 93% of patients and the consumption of anti-allergic medication decreased in more than 75% of patients	jimmyloser	Read Full Thread Reply
22/6/2018 10:40	Yes I think you are right AuDigger but I actually solidly expect that to make its assault on 40p not 30p. The setback was due to a lower allergy environment last year (thankfully for us sufferers) it certainly isn't like that this year! The company have in recent months progressed again and in spades. This as they said earlier, appears to be a potentially "TRANSFORMATIONAL" year. These things take time. impo/dyor	jimmyloser	Read Full Thread Reply
21/6/2018 18:42	Think its about time it launched an attack on 30p again!	audigger	Read Full Thread Reply
19/6/2018 12:26	Some big trades just gone through - is something brewing?	richsawko	Read Full Thread Reply
07/6/2018 17:34	Re jimmyloser 6 Jun '18 - 17:44 - 3433 of 3433 I'm invested here and also in Morphosys (MOR) which has an even more exciting product development pipeline IMO.	jemt0703	Read Full Thread Reply
06/6/2018 17:44	I should jolly well think so. We faithful will look back at this price and think that it was a mirage. I do not know of any business with a pipeline anywhere near as interesting as we have here.	jimmyloser	Read Full Thread Reply
29/5/2018 07:15	Underestimate what this team are doing at your peril! impo/dyor...The day will come when this business will be snapped up.....after stage 3, I suspect! Allergy Therapeutics PLC 29 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company") Positive new clinical data with house-dust mite immunotherapy House-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement Allergy experts present an overview of adjuvants at satellite symposium during EAACI 2018 29 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy(1) . This data will be presented today at the 37(th) Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany. The Group's modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017. In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline (p = <0.01). No patients presented with serious adverse events and no patients had to stop treatment due to any adverse event. Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the Group's planned recombinant peanut vaccine(3) and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy(4) . Other events held by the Group at EAACI included a satellite symposium entitled: "Adjuvants through the ages"(2) which provided a summary of how adjuvant technologies have evolved and how Allergy Therapeutics is spearheading the design and testing of state of the art allergen-specific immunotherapies. Manuel Llobet, Chief Executive Officer, commented: "We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company. The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."	jimmyloser	Read Full Thread Reply
22/5/2018 18:57	Some good info in this interview. Must admit that I thought they would be in to the phase 3 program earlier than the Q3 2019 recruitment date stated. Huge opportunity though and the barriers to entry for others will be high so a little more patience required.	audigger	Read Full Thread Reply
22/5/2018 18:51	Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018	gersemi	Read Full Thread Reply
22/5/2018 13:16	Afternoon, Short TV interview with both CEO Manuel Llobet and House broker Panmure Gordon's Healthcare Analyst Dr Mike Mitchell www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/	oshy92	Read Full Thread Reply

Chat Pages: 143 142 141 140 139 138 137 136 135 134 133 132 Older